MOC GPW Periodic report · PAP Biznes
Molecure SA (MOC) · Q1 2026 results
Share price: 5.49 zł · 2026-11-10
Results Q1 2026 vs Q1 2025 · year over year · published 18 May 2026 and 30 Apr 2025
Net loss narrowed year on year. The language turned more cautious.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss narrowed
Net income vs Q1 2025
Net income -4.1M vs -5.2M
Revenue −80.1%
2 · How the report reads
More cautious
Language tone vs last period
Report language: restrained for a company report — more cautious than in Q1 2025.
Weak signal: formal report language, not a call.
3 · What stood out Nothing unusual flagged this period.
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.
Restrained for a company report — more cautious than in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Sentences that drove the tone
“Liquidity risk – the risk that the Company will encounter difficulties in meeting obligations related to financial liabilities, the settlement of which takes place through the provision of funds or other types of financial assets.”
“Further stages of formal preclinical development and early phases of clinical development of the drug are performed based on cooperation with certified research centers (eng.”
“Molecure builds a flexible project development structure, combining own funds with external capital, including grants, while maintaining the possibility of further monetizing assets at various stages of their development.”
Full figures
PLN · PAP Biznes report (2026-05-18)
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | 118.8K | 597.7K | −80.1% |
| Operating income | -4.1M | -5.5M | Loss narrowed |
| Net income | -4.1M | -5.2M | Loss narrowed |
| EPS | -0.20 | -0.26 | Loss narrowed |
| P/E | 12-mo loss | 12-mo loss | — |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- Write-offs, expired, or uncollectible receivables reduce previously made write-downs of their value
- The Company conducted a private placement of Series K bearer ordinary shares as part of a capital increase.
- In the case of externally acquired projects with a documented date of commencement of clinical trials, the point of commencement of…
- The Company forecasts that in the majority of the programs
- The entity reassesses whether the contract is a lease or contains a lease only when the terms of the contract change.
Faded since Q1 2025
- Fading Write-offs are made against the remaining costs appropriate to the functional functions of fixed assets during the period in which a…
- Fading Written-off, expired, or uncollectible receivables reduce previously made write-downs of their value
Latest announcements
Official filings, newest first.
- Powołanie nowego Członka Rady Nadzorczej Spółki w drodze kooptacji · ESPI 31/2026
- Zmiany w Radzie Nadzorczej Spółki · ESPI 30/2026
- Half-year report · ESPI periodic
- Otrzymanie rekomendacji kontynuacji badania Fazy II dla cząsteczki OATD-01 u pacjentów z aktywną sarkoidozą płucną. · ESPI 29/2026
- Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu w dniu 29 czerwca 2026 roku · ESPI 28/2026
- Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie w dniu 29 czerwca 2026 roku · ESPI 27/2026
- Komunikat KDPW w sprawie rejestracji akcji serii K · ESPI 26/2026
- Dopuszczenie i wprowadzenie akcji do obrotu na rynku regulowanym GPW. · ESPI 25/2026